Indication

Mucopolysaccharidosis type I

**Mucopolysaccharidosis type I** (MPS I) is a rare, autosomal recessive lysosomal storage disease caused by mutations in the *IDUA* gene, leading to a deficiency of the enzyme alpha-L-iduronidase. Read more about Mucopolysaccharidosis type I

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Mucopolysaccharidosis type I therapies.

Showing 1–1 of 1 drugs

ALDURAZYME (laronidase)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS·MUCOPOLYSACCHARIDOSIS TYPE I
GENZYME
Filter & compare in the drug finder →Opens the drug finder with Mucopolysaccharidosis type I preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Mucopolysaccharidosis type I.

**Mucopolysaccharidosis type I** (MPS I) is a rare, autosomal recessive lysosomal storage disease caused by mutations in the *IDUA* gene, leading to a deficiency of the enzyme alpha-L-iduronidase.

This enzymatic defect prevents the degradation of the glycosaminoglycans dermatan sulfate and heparan sulfate, resulting in their progressive accumulation within tissues and organs across the body.

Clinically, the disease spans a continuous spectrum ranging from severe disease (historically Hurler syndrome) to attenuated forms (historically Hurler-Scheie and Scheie syndromes).

Hallmarks include progressive multisystem involvement characterized by skeletal deformities (dysostosis multiplex), coarse facial features, hepatosplenomegaly, corneal clouding, cardiac valve disease, upper airway obstruction, and, in severe cases, neurocognitive decline and shortened lifespan.

Personalize your experience

Follow Mucopolysaccharidosis type I and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it